… of early PET scan for further treatment efficacy with erlotinib or everolimus in patients with
NSCLC. However, by analyzing PET responses with regard to KRAS mutation, we saw four …

… Head and neck cancers are the sixth most common type of … Pharmacodynamic analysis of
KYSE180 xenografts confirmed … p-AKT in xenograft tumors treated with erlotinib was observed, …

… the in vivo pharmacodynamic effects in tumors and normal … the combination of panobinostat
and erlotinib is well tolerated, … a rational approach to assess the pharmacodynamic effects of …

… /pharmacodynamic (PK/PD) study was conducted in NSCLC … a higher risk of death in
patients with erlotinib C min,ss > … However, the molecular analysis of tumor biopsies at disease …

… druggable targets in head and neck cancer were identified with … sophisticated, patient- (and
tumor-) dependent analysis in … lung tumors with acquired resistance to gefitinib or erlotinib. …

… , esophageal, brain, and head and neck cancers.4, 5, 6 … , off-tumor effects in the skin with
evidence of rash, making skin … measuring skin toxicity after EGFR inhibition (afatinib, erlotinib, …

… of patients, allocation of treatment regimens is simply based on histological diagnosis and on
tumor location and disease staging (clinical risk assessments… of skin (basal cell carcinoma) …

… The North Central Cancer Treatment Group (now part of … in Oncology) trial N064B compared
gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib …

… We also propose to develop a molecular pharmacodynamic … We will assess vIII expression
using RT-PCR with RNA … Erlotinib in lung cancer - molecular and clinical predictors of …

… -normalization, which increases tumor microcirculation, which then … In the near future,
pharmacodynamics and pharmacokinetics … In vitro release of erlotinib, assessed as a percentage …